Insider Selling: Zoetis Inc (ZTS) CEO Sells 135,000 Shares of Stock
Zoetis Inc (NYSE:ZTS) CEO Juan Ramon Alaix sold 135,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total value of $12,359,250.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
NYSE:ZTS opened at $91.47 on Friday. The company has a market capitalization of $44.18 billion, a PE ratio of 37.94, a P/E/G ratio of 1.88 and a beta of 1.02. Zoetis Inc has a 1 year low of $60.44 and a 1 year high of $93.67. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.06. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the company earned $0.53 EPS. research analysts expect that Zoetis Inc will post 3.07 EPS for the current fiscal year.
Several research firms have weighed in on ZTS. Argus raised their price target on Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus raised their price target on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Morgan Stanley raised their price target on Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a report on Friday, August 3rd. BMO Capital Markets restated a “hold” rating and set a $82.00 price target on shares of Zoetis in a report on Thursday, August 2nd. Finally, Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the company a “buy” rating in a report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $90.53.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.